VisEn Launches New Cat B 680 FAST™ Fluorescence Molecular Imaging Agent

Extends VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Expanded Readouts of Key Protease Biomarkers in Research and Drug Development

BEDFORD, MA (January 19, 2010)—VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis. The new Cat B 680 FAST™ agent is designed to complement VisEn’s existing in vivo agent product lines, providing early imaging time points and an additional reporting wavelength for more multiplexing choices in cell-based and in vivo research study designs.

“We continue to be very pleased with the rapidly expanding capability and adoption of our fluorescence agents and FMT imaging systems in measuring key biologic pathways and biomarkers in vivo,” said Kirtland Poss, President and CEO of VisEn. “The new Cat B 680 FAST™ imaging agent is another new addition to the strong suite of VisEn agents that are becoming increasingly integrated as a standard in disease research today.”

VisEn’s proprietary fluorescence imaging agents and labels are designed to provide the industry’s broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn offers over 30 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, Cat K FAST™, Annexin-VivoTM, and now OsteoSense® 800, VivoTag® 800 and Cat B 750 and 680 FAST™. VisEn also offers specialized lines of in vivo agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes for custom agent development and its NanoSpark® labeling nanoparticles. They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging.

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn’s Fluorescence Molecular Tomography (FMT™) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn’s technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn’s in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT™) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn’s FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.

Contact:

Robert Sandler
SVP, Marketing
VisEn Medical Inc.
C. 416.274.8166
O. 647.350.1881
E. rsandler@visenmedical.com
W. www.visenmedical.com